rafivirumab

Modify Date: 2024-09-13 19:23:43

rafivirumab structure	Common Name	rafivirumab
	CAS Number	944548-37-2	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of rafivirumab

Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails[1][2][3].

Name	rafivirumab

Description	Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails[1][2][3].
Related Catalog	Research Areas >> Infection
In Vitro	Rafivirumab 显示出对一系列 RABV 分离株的中和作用[2]。 Rafivirumab 与 RABV 糖蛋白的抗原位点 I 结合[3]。 Rafivirumab 完全中和野生型 ERA439 和 N336D R346K，EC50 范围在 3 到 5 pg/mL 之间[3]。
In Vivo	Rafivirumab (3-12 μg/kg，肌肉注射) 与 CR4098 一起提高了感染蝙蝠狂犬病病毒的叙利亚仓鼠的存活率[2]。 Animal Model: Syrian hamsters infected with bat rabies viruses[2]. Dosage: 6, 12, 16, 18 or 24 μg/kg of CL184 (mixture of Rafivirumab and CR4098 in 1:1 protein ratio) Administration: i.m. Result: Increased survival rate.
References	[1]. Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45. [2]. Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48. [3]. Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403.